Skip to Content

Press Releases

Press Releases

Apr 13 2018
Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares
Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares JERUSALEM, April 13, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of 6.75 million of its ordinary shares, at a public offering price
Apr 11 2018
Intec Pharma Announces Pricing of $35.4 Million Public Offering of Ordinary Shares
JERUSALEM, April 11, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of 6.75 million of its ordinary shares at a public offering price of $5.25 per ordinary share. The gross proceeds of the offering are expected to be
Apr 10 2018
Intec Pharma Announces Proposed Public Offering of Ordinary Shares
JERUSALEM, April 10, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) today announced the launch of an underwritten public offering of its ordinary shares. In connection with this offering, Intec Pharma also intends to grant the underwriters a 30-day option to purchase up to an
Apr 04 2018
Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting
JERUSALEM, April 4, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) ("Intec" or "the Company") today announces that data collected from the Company's Phase 2 development program of its proprietary Accordion Pill™ oral drug delivery system have been accepted for poster presentation
Apr 03 2018
Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease
JERUSALEM, April 3, 2018 /PRNewswire/ -- Intec Pharma Ltd . (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary  Accordion Pill™  platform technology, today announced it will host a Key Opinion Leader (KOL)
Mar 26 2018
Intec Pharma Appoints Roger J. Pomerantz, M.D. to Board of Directors
JERUSALEM, March 26, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors. Dr. Pomerantz is President, Chief Executive Officer and Chairman of the Board of Directors of
Mar 12 2018
Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson's Disease
Global leader in formulation and film technology manufacture to establish commercial scale production capabilities for Intec's lead product candidate in FDA compliant facility JERUSALEM, March 12, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC) ("Intec" or the "Company") today announces
Mar 09 2018
Intec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and Business Update
More than 300 patients enrolled in pivotal Phase 3 ACCORDANCE Trial Gastroscopy safety sub-study successfully completed JERUSALEM, March 9, 2018 /PRNewswire/ --   Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) today announces financial results for the three and twelve months ended December 31,
Mar 05 2018
Intec Pharma, Ltd. to Present at Four Investor Conferences in March
JERUSALEM, March 5, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™ platform technology, today announced that the Company's officers will provide a corporate
Jan 31 2018
Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer
Industry Veteran brings over 30 years of experience in drug development JERUSALEM, Jan. 31, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ:  NTEC) (TASE:  NTEC ), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion
Displaying 11 - 20 of 74